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Abstract
Enchondromas and conventional central chondrosarcomas are, respectively, benign and
malignant hyaline cartilage-forming tumours that originate in the medulla of bone. In order
to gain a better understanding of the molecular process underlying malignant transformation
of enchondroma, and to investigate whether there is a biological difference between con-
ventional central cartilaginous tumours and those of enchondromatosis or with phalangeal
localization, a series of 64 enchondromas (phalanx, n = 21; enchondromatosis, n = 15) and
89 chondrosarcomas (phalanx, n = 17; enchondromatosis, n = 13) was collected. Indian
Hedgehog (IHH)/parathyroid hormone related peptide (PTHrP) signalling, an important
pathway in chondrocyte proliferation and differentiation within the normal growth plate,
was studied by immunohistochemical analysis of the expression of PTHrP, PTHR1, Bcl-
2, p21, cyclin D1, and cyclin E. Quantitative real-time PCR for IHH, PTCH, SMO, and
GLI2 was performed on a subset of tumours. The data show that IHH signalling is absent
in enchondromas and central chondrosarcomas, while PTHrP signalling is active. There
was no difference in the expression of any of the molecules between 35 enchondromas and
26 grade I central chondrosarcomas, indicating that PTHrP signalling is not important in
malignant transformation of enchondroma. Higher expression of PTHR1 and Bcl-2 was
associated with increasing histological grade in chondrosarcoma, suggesting involvement
in tumour progression. No difference was found between samples from enchondromatosis
patients and solitary cases, suggesting no difference in PTHrP signalling. A small subset
of phalangeal chondrosarcomas demonstrated down-regulation of PTHrP, which may be
related to its more indolent clinical behaviour. Thus, in both enchondromas and central
chondrosarcomas, PTHrP signalling is active and independent of IHH signalling, irrespective
of the presence or absence of enchondromatosis.
Copyright  2005 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Chondrosarcoma of bone is a malignant tumour
characterized by the formation of hyaline carti-
lage. The majority (83%) arise centrally within the
medullary cavity of bone (primary conventional cen-
tral chondrosarcomas) [1]. Transformation of enchon-
droma, a benign cartilaginous tumour, towards sec-
ondary central chondrosarcoma is thought to be very
rare (<1% of enchondromas) [1,2], and the mechanism
underlying malignant transformation is unknown. In
about 40% of central chondrosarcomas, remnants of
a previous, often undetected, enchondroma are found
next to the chondrosarcoma, implying that these cases
are strictly not primary, but secondary chondrosarco-
mas. Since these remnants are difficult to detect, it may
be that all central chondrosarcomas are secondary [3].
About 50% of enchondromas are found in small
bones of the hands and feet, while chondrosarcomas
are rare at this location [2] and, in contrast to
elsewhere, only rarely metastasize [4]. This raises
the question of whether cartilaginous tumours with
phalangeal localization are biologically different, or
whether localization determines prognosis.
While most enchondromas are solitary, patients with
enchondromatosis (Ollier disease, Maffucci syndrome)
have multiple enchondromas, scattered all over the
skeleton, often with unilateral predominance [5]. The
percentage of malignant transformation in patients
with enchondromatosis is much higher (25–30% per
patient) than in patients with solitary enchondromas
[1,2]. For enchondromas with phalangeal localiza-
tion, as well as enchondromas from enchondromatosis
patients, more worrisome histological features are tol-
erated [1,2], since they clinically behave in a more
indolent fashion.
The aims of our study were, firstly, to gain a bet-
ter understanding of the molecular process underlying
Copyright  2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Figure 1. Signalling within the normal human growth
plate. Indian Hedgehog (IHH), produced by pre-hypertrophic
chondrocytes, binds after diffusion mediated by heparan
sulphate proteoglycans (HSPG), to its receptor Patched
(PTCH). This results in the release of Smoothened (SMO) from
PTCH, which allows GLI molecules to act as transcriptional
activators of target genes [6]. These include genes from the IHH
pathway itself, such as PTCH and GLI [6,7]. Two other target
genes are cyclin E [8], involved in control of the transition of G1
to S-phase, and parathyroid hormone related protein (PTHrP)
[9]. PTHrP binds to its receptor (PTHR1) in the late proliferating
zone, resulting in up-regulation of the anti-apoptotic protein
Bcl-2 [10]. This inhibits further differentiation, thereby limiting
IHH-producing cells, closing the negative feedback loop.
Moreover, PTHR1 directly induces activation of the cyclin
D1 promoter [11]. FGFR3 activation leads to repression of
IHH/PTHrP signalling, and to up-regulation of the cell cycle
inhibitor p21 [12]. The molecules investigated in this study are
underlined
malignant transformation of enchondroma and, sec-
ondly, to investigate possible biological differences
between conventional central cartilaginous tumours
and those within the context of enchondromatosis or
with phalangeal localization.
Within the normal growth plate, the Indian Hedge-
hog (IHH)/parathyroid hormone related peptide
(PTHrP, PTHLH) negative feedback loop plays an
important role in the regulation of chondrocyte growth
and differentiation [6–12] (Figure 1). We investigated
molecules involved in PTHrP signalling by comparing
the protein expression of these signalling molecules
between the different subsets of tumours and assessed
whether putative differences in this signalling path-
way are associated with different clinical behaviour.
Since commercially available antibodies for IHH sig-
nalling molecules have been shown previously not to
work reliably in our hands [13], expression was stud-
ied with quantitative RT-PCR in a subset of tumours




Formalin-fixed, paraffin wax-embedded material was
used from 153 tumours (Table 1). Cases were collected
from (consultation) files of the Leiden University
Medical Center.
Patient data (Table 1) were obtained by review of
pathological specimens and reports, clinical charts,
and radiographs. Enchondromatosis was found in 28
patients. Histological grading for non-phalangeal cases
was performed according to Evans et al [14]. Clinico-
pathological features of phalangeal chondrosarcomas
have been described previously [4]. All tissue samples
were handled in a coded fashion, according to national
ethical guidelines (‘Code for Proper Secondary Use of
Human Tissue in The Netherlands’, Dutch Federation
of Medical Scientific Societies).
Immunohistochemistry
Antibodies, controls, and antigen retrieval are descri-
bed in Table 2. Antibodies were tested for their sus-
ceptibility to formalin fixation on appropriate tissues
fixed for 1, 3, 7, and 40 days, respectively, but none
revealed diminished staining reactivity. Internal posi-
tive controls were used (Table 2) to exclude absence of
staining due to decalcification. Negative controls were
performed using isotype controls. Immunohistochem-
ical staining was performed as described previously
[13].










Male vs female 13 vs 8 24 vs 19 8 vs 9 37 vs 35
Median age at diagnosis, years 25.4 (range 12.3–74.3) 37.8 (range 4.3–68.8) 61.6 (range 8–83.4) 50 (range 17.8–78.7)
Histological grade
Grade I — — —∗ 30
Grade II — — —∗ 30
Grade III — — —∗ 12
Enchondromatosis (Maffucci/Ollier) 7 (0/7) 8 (0/8) 3 (0/3) 10 (2/8)
Median follow-up, months 87.5 (range 2–226)† 83.5 (range 1–170)‡ 96 (range 15–249)§ 59.5 (range 2–212)||
∗ Histological grading in chondrosarcoma of the phalanx proved not useful [4].
Data available from † 14, ‡ 26, § 15, and || 64 patients.
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) Evaluation and scoring
Three observers (LBR, PCWH, and JVMGB) evalu-
ated the slides independently and discrepancies were
discussed. All observers were blinded towards clinico-
pathological data. Scoring was performed as described
previously [13]. In short, staining intensities (0 =
negative, 1 = weak, 2 = moderate, and 3 = strong
intensity) and the percentage of positive cells (0 =
0%, 1 = 1–24%, 2 = 25–49%, 3 = 50–74%, and
4 = 75–100% positive) were assessed. The slides
were scored positive if the combined values of the
staining intensity and the percentage of positive cells
were greater than 3 for PTHrP, PTHR1, and Bcl-2,
and greater than 0 for p21, cyclin D1 and cyclin E
[13,15,16]. For cyclin E and cyclin D1, lacking an
absolute internal control, cases were only scored neg-
ative if immunohistochemical data were available for
at least four other antibodies.
RNA isolation and quantitative PCR (qPCR)
RNA was isolated from 10 tumours [two phalangeal
enchondromas (enchondromatosis patients), one soli-
tary grade I chondrosarcoma, five grade II chondrosar-
comas (three from enchondromatosis patients), and
two solitary grade III chondrosarcomas] and seven
normal samples (four growth plates and three normal
resting cartilage samples) as described previously [17].
One microgram of total RNA was converted to
complementary DNA (cDNA) by using AMV reverse
transcriptase (Roche Applied Science). qPCR was per-
formed for IHH, PTCH, SMO, GLI2, and four normal-
ization genes (CPSF6, GPR108, HNRPH1, and SRPR;
primers and qPCR conditions are available on request).
The latter were selected from expression profiling
experiments of enchondromas, central chondrosar-
comas (different grades), normal epiphyseal growth
plates, and resting cartilage samples, demonstrating
the least variation between all samples (unpublished
data). qPCR amplification was performed according
to the manufacturer’s protocol. For each gene, a stan-
dard curve, consisting of a mixture of eight samples,
was included to calculate the relative starting quantity
of each gene, which was used in normalization and
statistical analysis.
Geometric averaging of the candidate normalization
genes [18] was performed to acquire reliable normal-
ization of the qPCR experiments. This method pro-
vides a normalization factor (NF) that is representative
for the amount of mRNA in each sample. Expression
levels in the tumours were related to those of four nor-
mal growth plates, where IHH signalling is known to
be active [9].
Statistical analysis
Comparison of immunohistochemical data between
two different groups was analysed using Pearson
chi-square/Fisher’s exact test, two-sided. Correlation
between staining and histological grade was tested
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Table 3. Scoring results for immunohistochemical staining in enchondromas and chondrosarcomas
PTHrP PTHR1 Bcl-2 Cyclin D1 Cyclin E p21
pos∗ % pos† pos % pos pos % pos pos % pos pos % pos pos % pos
EC Solitary 32/32 100 7/19 37 4/25 16 9/18 50 0/17 0 27/30 90
EC-tosis 6/6 100 2/4 50 1/4 25 1/2 50 0/2 0 3/3 100
Total 38/38 100 9/23 39 5/29 17 10/20 50 0/19 0 30/33 91
EC-P Solitary 14/14 100 10/14 71 9/13 69 9/13 69 1/13 7 14/14 100
EC-tosis 5/5 100 3/4 75 2/3 67 2/3 67 0/1 0 3/3 100
Total 19/19 100 13/18 72 11/16 69 11/16 69 1/14 7 17/17 100
All EC Solitary 46/46 100 17/33 51 13/38 34 18/31 58 1/30 3 41/44 93
EC-tosis 11/11 100 5/8 63 3/7 43 3/5 60 0/3 0 6/6 100
Total 57/57 100 17/36 47 16/45 36 21/36 58 1/33 3 47/50 94
CS-I Solitary 26/26 100 17/25 68 6/22 27 14/23 61 1/21 5 19/20 95
EC-tosis 2/2 100 1/1 100 1/2 50 1/1 100 — — 1/1 100
Total 28/28 100 18/26 69 7/24 29 15/24 63 1/21 5 20/21 95
CS-II Solitary 25/25 100 21/25 84 19/22 86 18/22 81 1/22 5 19/21 90
EC-tosis 4/4 100 3/3 100 1/3 33 2/3 67 0/2 0 3/3 100
Total 29/29 100 24/28 86 20/25 80 20/25 80 1/24 4 22/24 92
CS-III Solitary 10/10 100 8/10 80 5/8 63 4/8 50 1/7 14 7/7 100
EC-tosis 2/2 100 1/1 100 1/1 100 1/1 100 0/1 0 1/1 100
Total 12/12 100 9/11 82 6/9 67 5/9 56 1/8 13 8/8 100
CS-P Solitary 11/14 79 5/9 56 5/10 50 5/10 50 0/2 0 10/10 100
EC-tosis 1/2 50 1/2 50 1/1 100 1/1 100 — — 1/1 100
Total 12/16 75 6/11 55 6/11 55 6/11 55 0/2 0 11/11 100
All CS Solitary 72/75 96 51/69 74 35/62 56 41/63 65 3/52 6 55/58 95
EC-tosis 9/10 90 6/7 86 4/7 57 5/6 83 0/3 0 6/6 100
Total 81/85 95 57/76 75 39/69 57 46/69 67 3/55 5 61/64 95
∗ pos: number of positive samples/number of samples that could be evaluated.
† % pos: percentage of positive samples.
EC = enchondroma; CS = chondrosarcoma; EC-tosis = enchondromatosis; -P = located in the phalanx
with chi-square, linear by linear. Correlation with
outcome was analysed using the log-rank test. To
correct for multiple testing, p values ≤ 0.01 were
considered significant. Relative RNA expression levels
from the different tumour groups were compared with
growth plates by one-way ANOVA with Bonferroni




PTHrP signalling molecules are present in enchon-
dromas and central chondrosarcomas. p21 and PTHrP
were positive in almost all samples, whereas PTHR1,
Bcl-2, and cyclin D1 showed more variation (Table 3).
Cyclin E was only minimally positive in 4 of 88
samples and therefore not used in further statistical
analysis. A variable number of samples, ranging from
11 (PTHrP) to 29 (cyclin D1), could not be evaluated
due to detachment from the glass slides.
Statistical analysis of immunohistochemistry
Enchondroma vs chondrosarcoma grade I
No significant difference was found for any of the
molecules investigated between 35 non-phalangeal
solitary enchondromas and 26 solitary conventional
central chondrosarcomas, grade I (p = 0.066–1.00);
between the 21 enchondromas of the phalanx and 17
chondrosarcomas of the phalanx [p = 0.035 (PTHrP)–
1.00]; or between 15 enchondromas and 13 chon-
drosarcomas in patients with enchondromatosis (p =
0.267–1.00).
Phalangeal localization vs localization elsewhere
Phalangeal chondrosarcomas were compared
with grade II conventional central chondrosarco-
mas located elsewhere, based on similar histologi-
cal features [4]. Only PTHrP differed significantly,
being expressed in 12 of 16 (75%) phalangeal chon-
drosarcomas compared with 100% (n = 25) of grade
II chondrosarcomas located elsewhere (p = 0.010)
(Figure 2).
In addition, expression of Bcl-2 was found in
9 of 13 (69%) solitary phalangeal enchondromas
compared with 4 of 25 (16%) solitary enchondromas
located elsewhere (p = 0.001). A trend was found
towards higher expression of PTHR1 in all phalangeal
enchondromas [13 of 18 (72%) positive] compared
with all enchondromas elsewhere [9 of 23 (39%)
positive] (p = 0.072).
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Figure 2. Lack of PTHrP expression in a subset of phalangeal chondrosarcomas. (A) PTHrP expression is absent in a phalangeal
chondrosarcoma, with a positive internal control (inset), while (B) strong expression of PTHrP is found in grade II chondrosarcoma
Figure 3. Immunohistochemical staining for Bcl-2 and PTHR1 in low- and high-grade conventional central chondrosarcoma.
PTHR1 (A, B) and Bcl-2 (C, D) staining shows low intensity and a low percentage of positive cells in grade I conventional central
chondrosarcomas (A and C, arrows), while increased staining is found in high-grade conventional central chondrosarcomas (B and
D, grade III)
Enchondromatosis vs solitary cases
Expression was compared both for all tumours together
and for each subtype separately (eg enchondroma;
enchondroma of the phalanx; chondrosarcoma grade
I, II, and III). No difference was observed for any of
the proteins.
Low-grade vs high-grade conventional central
chondrosarcomas
Analysing all samples, increased PTHR1 and Bcl-
2 expression correlated with increasing histologi-
cal grade (p = 0.002 and p = 0.000, respectively)
(Figure 3). For Bcl-2, this was mainly based on the
increased percentage of positive cells (p = 0.000),
while for PTHR1, both the intensity and the percent-
age of cells increased (both p = 0.000). Histological
grade correlated with disease-free or metastasis-free
survival (p < 0.0000 for both parameters), but none of
the molecules was an independent significant predictor
of outcome.
Correlation between expression of the different
proteins
A positive correlation was found between Bcl-2 and
PTHR1 (p = 0.000).
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Table 4. Average mRNA expression of IHH, PTCH, SMO, and
GLI2 per subgroup, relative to the average expression in the
human growth plate
Subtypes IHH PTCH SMO GLI2
Resting cartilage (n = 3) 0.28 0.10∗ 1.51 0.70
Human growth plate (n = 4) 1.00 1.00 1.00 1.00
EC-P (n = 2) 0.48 0.48 0.54 0.22
CS-I (n = 1)† 0.20 0.01 — 0.21
CS-II (n = 5) 0.49 0.06∗ 0.73 0.23∗
CS-III (n = 2) 0.51 0.06∗ 0.63 0.15∗
∗ Significant difference compared with growth plate.
† Statistical test could not be performed on this group since it contains
only one sample.
EC = enchondroma; CS = chondrosarcoma; -P = located in the
phalanx.
qPCR
Expression of IHH, PTCH, GLI2, and SMO was
present in the growth plate specimens. Expression of
PTCH, which can be used as a read-out system for
HH activity, and GLI2 was dramatically decreased
in the tumours compared with the normal growth
plate (Table 4). Although the sample size is small,
PTCH expression was lower in normal cartilage (p =
0.019) and chondrosarcoma grade II (p = 0.000) and
III (p = 0.000), and GLI2 expression was lower in
chondrosarcoma grade II (p = 0.020) and III (p =
0.013) compared with growth plates. No differences
were found comparing solitary and enchondromatosis-
related samples.
Discussion
In this study, we have demonstrated active PTHrP sig-
nalling in both enchondroma and central chondrosar-
coma by protein expression of PTHrP, PTHR1, Bcl-2,
and cyclin D1. Expression of PTCH RNA was very
low or absent. Activation of IHH signalling leads
to the activation of target genes, including PTCH
and GLI [6,7]. Therefore, transcriptional activation of
PTCH is used as a reporter for Hedgehog signalling
[6]. The absence of PTCH thus indicates that IHH sig-
nalling is not active in enchondroma and central chon-
drosarcoma. In Drosophila, cyclin E is downstream of
Hedgehog [8]. We detected cyclin E expression in only
four samples, indicating that this molecule is not very
important in the development of enchondromas and/or
chondrosarcomas, which corroborates the absence of
IHH signalling. Thus, PTHrP signalling in enchon-
droma and central chondrosarcoma is not activated by
IHH but by other, as yet unknown, mechanisms. TGF-
beta is a good candidate since it was reported to induce
PTHrP [19] and is expressed in chondrosarcoma [20].
Our findings confirm the importance of PTHrP
signalling in cartilage neoplasia, as previously shown
in chondroblastoma [15] and secondary peripheral
chondrosarcoma [13]. Since no difference was found
between enchondroma and chondrosarcoma, it seems
that PTHrP signalling does not play a vital role
in malignant transformation of enchondroma towards
secondary central chondrosarcoma.
About 17% of chondrosarcomas develop within the
cartilaginous cap of a pre-existing benign osteochon-
droma (secondary peripheral chondrosarcomas) [21].
In osteochondromas, PTHrP signalling is absent [13],
most likely due to mutational inactivation and/or loss
of EXT genes [22]. Upon malignant transformation,
PTHrP and Bcl-2 expression is up-regulated [13]. This
makes the absence of PTHrP signalling specific for
osteochondromas, since PTHrP signalling is active in
enchondromas and chondroblastomas [15].
We have confirmed that higher Bcl-2 expression is
associated with progression towards high-grade central
chondrosarcoma, as suggested by our previous results
[13]. Bcl-2 negatively controls programmed cell death
in growth plate chondrocytes both in situ and in vitro
[10]. Expression of PTHR1, using a monoclonal
antibody, correlated with increasing histological grade,
which was not found with the polyclonal antibody used
in our earlier pilot series [13].
In the present study, PTHrP was expressed in almost
all samples, while previously [13] expression seemed
to increase with grade. However, this was done using a
much smaller sample size and a different batch of the
polyclonal antibody. Although no distinction between
central and peripheral tumours was made, expression
of PTHrP and PTHR1 has also been examined by
others, showing up-regulation with grade [23,24].
Thus, in enchondroma and central chondrosarcoma,
PTHrP signalling is active and seems to increase
with histological grade, in parallel with the increased
proliferative activity.
One of our goals was to investigate whether pha-
langeal cartilaginous tumours are biologically different
from other sites. Phalangeal chondrosarcomas display
locally aggressive behaviour with very low metastatic
potential (< 2%) [4]. Remarkably, only 4 of 142
tumours were PTHrP-negative and all four were chon-
drosarcomas of the phalanx. This down-regulation of
PTHrP signalling, which is also found in osteochon-
droma [13], may be specific for at least a subset of pha-
langeal chondrosarcomas and may be related to their
more indolent behaviour. Combined with the slightly
lower proliferation rate and slightly lower percentage
of p53 overexpression in phalangeal chondrosarcomas
reported previously [4], these data support the sugges-
tion that chondrosarcomas of the phalanx are indeed
biologically different.
Expression of Bcl-2 and PTHR1 was higher in soli-
tary phalangeal enchondromas than in solitary enchon-
dromas elsewhere. Since PTHR1 and Bcl-2 expression
correlates with increasing histological grade in non-
phalangeal chondrosarcomas, these results are prob-
ably associated with the more worrisome histologi-
cal features tolerated in phalangeal enchondroma, but
leading to a diagnosis of chondrosarcoma at other
localizations [1,2].
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Finally, no differences were found between solitary
and enchondromatosis-related tumours. An activating
mutation has been reported in PTHR1 in two enchon-
dromatosis patients [25]. The mutation would lead to
up-regulation of IHH signalling [25]. Here we demon-
strate absence of IHH signalling in two enchondro-
mas and three chondrosarcomas from enchondromato-
sis patients. In addition, we previously screened 31
patients and could not find any PTHR1 mutations [26].
These data again indicate that PTHR1 is not the culprit
for enchondromatosis.
p21 was expressed in the majority of tumours.
p21 inhibits chondrocyte proliferation, reducing the
number of IHH-expressing cells in the growth plate
[12]. There may be a role for p21 in the down-
regulation of IHH signalling that we observed.
In conclusion, we have demonstrated that IHH sig-
nalling is absent in enchondromas and central conven-
tional chondrosarcomas, indicating that although this
pathway is important in normal chondrocyte growth
and differentiation, it is not involved in enchondromas
and chondrosarcomas. However, PTHrP signalling is
active in both enchondromas and conventional central
chondrosarcomas, confirming its importance in growth
and differentiation of neoplastic cartilage and suggest-
ing activation independent of IHH signalling.
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